|
GTF3C4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.70820066162037E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.88959958791202E-10 |
| Normal-vs-Stage2 |
1.37010000000881E-06 |
| Normal-vs-Stage3 |
7.07539582478489E-11 |
| Normal-vs-Stage4 |
3.10573788908641E-12 |
| Stage1-vs-Stage2 |
5.312600E-01 |
| Stage1-vs-Stage3 |
4.247800E-01 |
| Stage1-vs-Stage4 |
1.949950E-02 |
| Stage2-vs-Stage3 |
2.986600E-01 |
| Stage2-vs-Stage4 |
5.241900E-02 |
| Stage3-vs-Stage4 |
1.699410E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.05610023135728E-11 |
| Normal-vs-AfricanAmerican |
6.49389999999306E-05 |
| Normal-vs-Asian |
1.36019973062673E-10 |
| Caucasian-vs-AfricanAmerican |
3.619400E-01 |
| Caucasian-vs-Asian |
4.293200E-01 |
| AfricanAmerican-vs-Asian |
1.559760E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.57830423677774E-11 |
| Normal-vs-Female |
1.56609947232766E-10 |
| Male-vs-Female |
2.390800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.99489980090561E-10 |
| Normal-vs-Age(41-60Yrs) |
4.5852210917019E-14 |
| Normal-vs-Age(61-80Yrs) |
5.33599830987441E-11 |
| Normal-vs-Age(81-100Yrs) |
1.562300E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.357000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.772600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.227400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.474800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.206800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.243000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.736400E-02 |
| Classical-VS-Follicular |
4.634600E-01 |
| Classical-VS-Other |
1.140360E-01 |
| Classical-VS-Normal |
1.08090003614336E-09 |
| Tall-VS-Follicular |
1.819820E-01 |
| Tall-VS-Other |
4.220800E-01 |
| Tall-VS-Normal |
5.12729858570538E-11 |
| Follicular-VS-Other |
2.368600E-01 |
| Follicular-VS-Normal |
8.28720425616325E-11 |
| Other-VS-Normal |
2.363600E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.59792187762287E-14 |
| Normal-vs-N1 |
6.64857058296775E-12 |
| N0-vs-N1 |
3.970200E-02 |
|
|
